Technical Analysis for STTK - Shattuck Labs, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Up |
| Historical STTK trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Hot IPO Pullback | Bullish Swing Setup | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| NR7 | Range Contraction | 0.18% | |
| Inside Day | Range Contraction | 0.18% | |
| New 52 Week Closing High | Bullish | -1.13% | |
| Up 3 Days in a Row | Strength | -1.13% | |
| Up 4 Days in a Row | Strength | -1.13% | |
| Up 5 Days in a Row | Strength | -1.13% | |
| New 52 Week Closing High | Bullish | 3.56% | |
| Up 3 Days in a Row | Strength | 3.56% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Rose Above Previous Day's High | 2 days ago | |
| Outside Day | 2 days ago | |
| Up 2% | 2 days ago | |
| Up 1% | 2 days ago | |
| 60 Minute Opening Range Breakout | 3 days ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian cancer. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was founded in 2016 and is headquartered in Austin, Texas.
Biotechnology Health Cancer Life Sciences Pharmaceutical Industry Treatment Of Cancer Clinical Trial Lymphoma Ovarian Cancer Design Of Experiments Astrazeneca Autoimmune Disease Seattle Genetics Clinical Research Advanced Solid Tumors Treatment Of Ovarian Cancer Clinical Pharmacology Takeda Pharmaceutical Company
Biotechnology Health Cancer Life Sciences Pharmaceutical Industry Treatment Of Cancer Clinical Trial Lymphoma Ovarian Cancer Design Of Experiments Astrazeneca Autoimmune Disease Seattle Genetics Clinical Research Advanced Solid Tumors Treatment Of Ovarian Cancer Clinical Pharmacology Takeda Pharmaceutical Company
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 22.9 |
| 52 Week Low | 17.51 |
| Average Volume | 172,565 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 0.00 |
| 10-Day Moving Average | 20.51 |
| Average True Range | 0.00 |
| ADX | 0.0 |
| +DI | 0.00 |
| -DI | 0.00 |
| Chandelier Exit (Long, 3 ATRs ) | N/A |
| Chandelier Exit (Short, 3 ATRs ) | N/A |
| Upper Bollinger Band | 0.00 |
| Lower Bollinger Band | 0.00 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.00 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 23.48 | ||||
| Resistance 3 (R3) | 23.46 | 22.87 | 23.20 | ||
| Resistance 2 (R2) | 22.87 | 22.45 | 22.89 | 23.11 | |
| Resistance 1 (R1) | 22.34 | 22.18 | 22.61 | 22.36 | 23.01 |
| Pivot Point | 21.75 | 21.75 | 21.89 | 21.77 | 21.75 |
| Support 1 (S1) | 21.22 | 21.33 | 21.49 | 21.24 | 20.59 |
| Support 2 (S2) | 20.63 | 21.06 | 20.65 | 20.49 | |
| Support 3 (S3) | 20.10 | 20.63 | 20.40 | ||
| Support 4 (S4) | 20.12 |
